Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Should l Buy EVGN?
Evogene and Shanghai Lishan Biopharmaceuticals announced that Biomica, Evogene's subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic designed to enhance anti-tumor immune activity. BMC128 was developed by Biomica and is currently completing a Phase 1 clinical study, showing promising early clinical results. BMC128 is a live biopharmaceutical consortium composed of four human gut bacterial strains with defined functional capabilities that enhance responses to immunotherapy and stimulate anti-tumor immune activity. BMC128 is currently completing a Phase 1 clinical study in renal cell carcinoma and non-small cell lung cancer and has demonstrated encouraging early clinical promise. Under the agreement, Lishan Biotech will assume responsibility for global clinical development, manufacturing, and commercialization of BMC128. Biomica will be eligible to receive development milestone payments and royalties on future commercial sales, in accordance with an agreed-upon schedule. Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and to pursue regulatory filings in both China and the United States for future commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVGN
Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
Low
2.50
Averages
2.50
High
2.50
Current: 1.100
Low
2.50
Averages
2.50
High
2.50
About EVGN
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evogene and Lishan Biotech Sign Exclusive Licensing Agreement
- Exclusive Licensing Agreement: Evogene's subsidiary Biomica has entered into a global exclusive licensing agreement with China's Lishan Biotech for BMC128, a therapy designed to enhance anti-tumor immune activity, marking a strategic collaboration in the microbiome treatment space.
- Clinical Research Progress: BMC128 is currently undergoing Phase 1 clinical studies for renal cell carcinoma and non-small cell lung cancer, with preliminary results indicating excellent safety and tolerability, alongside a high proportion of patients achieving stable disease during treatment, suggesting its potential clinical value.
- Global Development Responsibility: Under the agreement, Lishan Biotech will take charge of the global clinical development, manufacturing, and commercialization of BMC128, which will accelerate the therapy's market introduction and provide Evogene with milestone payments and royalties on future sales.
- Strategic Collaboration Outlook: Lishan Biotech plans to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in both China and the United States, expected to offer innovative treatment options for cancer patients and further solidify both parties' market positions in the biopharmaceutical sector.
See More
EverGen Infrastructure Closes $13M Financing to Enhance Financial Flexibility
- Financing Structure Optimization: EverGen has secured a $13 million asset-level debt agreement with Farm Credit Canada, significantly reducing overall debt service costs and strengthening the company's financial foundation to support strategic goals for 2026.
- Corporate Debt Repayment: The company successfully repaid $12 million of corporate debt, reducing the remaining balance to approximately $1.1 million, which alleviates financial burdens and provides funding for future organic growth and optimization projects.
- Successful Equity Financing: EverGen closed a non-brokered private placement raising approximately $1.9 million by issuing 3,152,441 common shares at $0.60 each, reflecting strong market confidence in the company's operational performance and platform potential.
- Strategic Development Opportunity: This financing not only enhances the company's capital flexibility but also lays the groundwork for expansion in the renewable natural gas sector, expected to accelerate growth in agricultural waste solutions.
See More
EverGen Infrastructure Closes $13M Financing to Optimize Debt Structure
- Financing Structure Optimization: EverGen has secured a $13 million asset-level debt agreement with Farm Credit Canada, significantly reducing overall debt service costs, thereby enhancing financial stability and laying the groundwork for strategic repositioning in 2026.
- Corporate Debt Repayment: The company successfully repaid $12 million of corporate debt, reducing the remaining balance to approximately $1.1 million, which not only alleviates financial burdens but also enhances future financing flexibility.
- Equity Financing Support: EverGen completed a non-brokered private placement raising approximately $1.9 million by issuing 3,152,441 common shares at $0.60 each, providing additional operational funds to support its sustainability strategy.
- Increased Market Confidence: The successful financing reflects institutional investor confidence and provides EverGen with the necessary capital to accelerate growth in the renewable natural gas sector, particularly in organic and agricultural waste solutions.
See More
EverGen Infrastructure Closes $13M Financing, Restructures Debt
- Successful Financing: EverGen has successfully closed a $13 million asset-level debt facility through its wholly-owned subsidiary Fraser Valley Biogas Ltd., strengthening the company's financial foundation and setting the stage for strategic repositioning heading into 2026.
- Debt Repayment Plan: The financing will primarily be used to repay $12 million of corporate debt, which is expected to materially reduce the company's annual debt service costs, thereby enhancing overall financial health.
- Private Placement Completion: The company also completed the second tranche of its non-brokered private placement, raising approximately $1.9 million by issuing 3,152,441 common shares, further bolstering working capital and operational capabilities.
- Increased Shareholder Confidence: CEO Chase Edgelow noted that this financing not only aligns with the company's assets but also signals institutional confidence, providing flexibility for sustainable growth in the future.
See More
EverGen Infrastructure Updates: $13M Debt Refinancing and $2M Private Placement
- Debt Restructuring Progress: EverGen has signed a $13 million credit agreement with Farm Credit Canada through its subsidiary Fraser Valley Biogas, which is expected to enhance the company's financial structure and support future operational growth.
- Private Placement Expansion: The company plans to issue up to 1,166,667 common shares in a second non-brokered private placement, aiming to raise $2 million for debt repayment and working capital, thereby enhancing financial flexibility.
- Successful Initial Placement: EverGen completed its first private placement in May 2025, issuing 8,333,333 common shares for $5 million, providing crucial funding for the company's reorganization and demonstrating market confidence in its strategic direction.
- Optimistic Future Outlook: The company anticipates continued benefits from these financing activities in 2026, driving the expansion of renewable natural gas infrastructure to combat climate change and meet the growing demand for clean energy.
See More
EverGen Infrastructure Corp. Updates on $13M Debt Refinancing and $2M Private Placement
- Debt Restructuring Progress: EverGen has signed a $13 million Credit Agreement with Farm Credit Canada through its wholly owned subsidiary FVB, which is expected to improve the company's financial structure and support future operational growth.
- Private Placement Plans: The company plans to issue up to 3,333,334 common shares in a second non-brokered private placement, expected to raise $2 million primarily for debt repayment and working capital, thereby enhancing financial flexibility.
- Successful First Tranche: EverGen completed its first tranche financing in May 2025, issuing 8,333,333 common shares for gross proceeds of $5 million, providing funding support for the company's reorganization transaction and demonstrating market confidence in its strategy.
- Positive Future Outlook: With the advancement of debt restructuring and private placement, EverGen is expected to lay a solid foundation for 2026, enhancing its competitive position in the renewable energy sector.
See More
Evogene and Lishan Biotech Sign Exclusive Licensing Agreement
- Exclusive Licensing Agreement: Evogene's subsidiary Biomica has entered into a global exclusive licensing agreement with China's Lishan Biotech for BMC128, a therapy designed to enhance anti-tumor immune activity, marking a strategic collaboration in the microbiome treatment space.
- Clinical Research Progress: BMC128 is currently undergoing Phase 1 clinical studies for renal cell carcinoma and non-small cell lung cancer, with preliminary results indicating excellent safety and tolerability, alongside a high proportion of patients achieving stable disease during treatment, suggesting its potential clinical value.
- Global Development Responsibility: Under the agreement, Lishan Biotech will take charge of the global clinical development, manufacturing, and commercialization of BMC128, which will accelerate the therapy's market introduction and provide Evogene with milestone payments and royalties on future sales.
- Strategic Collaboration Outlook: Lishan Biotech plans to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in both China and the United States, expected to offer innovative treatment options for cancer patients and further solidify both parties' market positions in the biopharmaceutical sector.
See More
EverGen Infrastructure Closes $13M Financing to Enhance Financial Flexibility
- Financing Structure Optimization: EverGen has secured a $13 million asset-level debt agreement with Farm Credit Canada, significantly reducing overall debt service costs and strengthening the company's financial foundation to support strategic goals for 2026.
- Corporate Debt Repayment: The company successfully repaid $12 million of corporate debt, reducing the remaining balance to approximately $1.1 million, which alleviates financial burdens and provides funding for future organic growth and optimization projects.
- Successful Equity Financing: EverGen closed a non-brokered private placement raising approximately $1.9 million by issuing 3,152,441 common shares at $0.60 each, reflecting strong market confidence in the company's operational performance and platform potential.
- Strategic Development Opportunity: This financing not only enhances the company's capital flexibility but also lays the groundwork for expansion in the renewable natural gas sector, expected to accelerate growth in agricultural waste solutions.
See More
EverGen Infrastructure Closes $13M Financing to Optimize Debt Structure
- Financing Structure Optimization: EverGen has secured a $13 million asset-level debt agreement with Farm Credit Canada, significantly reducing overall debt service costs, thereby enhancing financial stability and laying the groundwork for strategic repositioning in 2026.
- Corporate Debt Repayment: The company successfully repaid $12 million of corporate debt, reducing the remaining balance to approximately $1.1 million, which not only alleviates financial burdens but also enhances future financing flexibility.
- Equity Financing Support: EverGen completed a non-brokered private placement raising approximately $1.9 million by issuing 3,152,441 common shares at $0.60 each, providing additional operational funds to support its sustainability strategy.
- Increased Market Confidence: The successful financing reflects institutional investor confidence and provides EverGen with the necessary capital to accelerate growth in the renewable natural gas sector, particularly in organic and agricultural waste solutions.
See More
EverGen Infrastructure Closes $13M Financing, Restructures Debt
- Successful Financing: EverGen has successfully closed a $13 million asset-level debt facility through its wholly-owned subsidiary Fraser Valley Biogas Ltd., strengthening the company's financial foundation and setting the stage for strategic repositioning heading into 2026.
- Debt Repayment Plan: The financing will primarily be used to repay $12 million of corporate debt, which is expected to materially reduce the company's annual debt service costs, thereby enhancing overall financial health.
- Private Placement Completion: The company also completed the second tranche of its non-brokered private placement, raising approximately $1.9 million by issuing 3,152,441 common shares, further bolstering working capital and operational capabilities.
- Increased Shareholder Confidence: CEO Chase Edgelow noted that this financing not only aligns with the company's assets but also signals institutional confidence, providing flexibility for sustainable growth in the future.
See More
EverGen Infrastructure Updates: $13M Debt Refinancing and $2M Private Placement
- Debt Restructuring Progress: EverGen has signed a $13 million credit agreement with Farm Credit Canada through its subsidiary Fraser Valley Biogas, which is expected to enhance the company's financial structure and support future operational growth.
- Private Placement Expansion: The company plans to issue up to 1,166,667 common shares in a second non-brokered private placement, aiming to raise $2 million for debt repayment and working capital, thereby enhancing financial flexibility.
- Successful Initial Placement: EverGen completed its first private placement in May 2025, issuing 8,333,333 common shares for $5 million, providing crucial funding for the company's reorganization and demonstrating market confidence in its strategic direction.
- Optimistic Future Outlook: The company anticipates continued benefits from these financing activities in 2026, driving the expansion of renewable natural gas infrastructure to combat climate change and meet the growing demand for clean energy.
See More
EverGen Infrastructure Corp. Updates on $13M Debt Refinancing and $2M Private Placement
- Debt Restructuring Progress: EverGen has signed a $13 million Credit Agreement with Farm Credit Canada through its wholly owned subsidiary FVB, which is expected to improve the company's financial structure and support future operational growth.
- Private Placement Plans: The company plans to issue up to 3,333,334 common shares in a second non-brokered private placement, expected to raise $2 million primarily for debt repayment and working capital, thereby enhancing financial flexibility.
- Successful First Tranche: EverGen completed its first tranche financing in May 2025, issuing 8,333,333 common shares for gross proceeds of $5 million, providing funding support for the company's reorganization transaction and demonstrating market confidence in its strategy.
- Positive Future Outlook: With the advancement of debt restructuring and private placement, EverGen is expected to lay a solid foundation for 2026, enhancing its competitive position in the renewable energy sector.
See More
